2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5543 Diverse hematologic presentations associated with SH2B3 variants in a single-center sequencing cohort

Jack Tellerday, MD, Marshall Horwitz, MD, PhD2, David Wu, MD, PhD3, Sioban Keel, MD4
1 University of Washington, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 University of Washington, Seattle, Washington, United States
4 University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States

Introduction:

SH2B3 encodes an SH2B adaptor protein that negatively regulates cytokine receptor signaling pathways in hematopoietic cells including Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling. Germline and somatic variants have been identified in myeloid and lymphoid neoplasms including myeloproliferative neoplasms (MPN) as well as in isolated hematologic abnormalities. In MPNs, SH2B3 variants occur both with canonical driver variants (JAK2, CALR, MPL) and in triple-negative (TN) disease. Biallelic germline SH2B3 variants cause a syndrome of myeloproliferation and multi-organ autoimmunity. The phenotype of heterozygous germline SH2B3 variants is incompletely characterized and may be allele-specific; reported associations include immune dysregulation and hematologic disease susceptibility. We analyzed the spectrum of variants and disease associations in a cohort who underwent clinical sequencing at our center.

Methods:

An internal University of Washington database was used to identify adults with documented SH2B3 variants in blood, bone marrow, or tissue detected by genetic sequencing performed for known or suspected myeloid neoplasms. Clinical data were extracted from the electronic health record. Variants were curated for pathogenicity or of uncertain significance (VUS) by the clinical pipeline. Presumptive germline variants were classified based on a variant allele frequency (VAF) of >30%, persistence of VAF despite change in disease state if serial somatic testing existed, and absence of co-occurring variants with similar VAFs suggesting a somatic clone. In one case, germline status was confirmed by detection of the variant in cultured skin fibroblast DNA.

Results:

A total of 86 patients harboring 54 SH2B3 variants were identified. Phenotypes included acute myeloid leukemia (AML, 29), myelofibrosis (MF, 11), myelodysplastic syndrome (MDS, 11), isolated cytoses/cytopenias (11), other myeloid leukemia (7), lymphoid disease (5), multiple myeloma (MM, 3), polycythemia vera (PV, 3), essential thrombocythemia (ET, 2), common variable immunodeficiency (CVID, 2), clonal hematopoiesis of indeterminate potential (1), and aplastic anemia (1). VAF ranged from 3%-97%.

32 of the total variants are not reported on ClinVar. The majority (67%) of variants are missense. 14 variants localize to the SH2 domain, 10 to the PH domain, one to the dimerization domain, and 29 outside of these domains. Six variants occurred at least four times: S186I (4), R566W (4), E78K (4), E208Q (5), E395K (5), and E400K (14).
AlphaMissense scoring predicts 10 of the novel variants to be likely pathogenic (range .071-.997). Double hit variants occurred in 7/86 patients (8.1%).

 
Among patients with MPNs (16), one patient had TN disease, developing PMF at the age of 48. The majority of patients in this group also had JAK2 variants. 5 of these patients possessed the same SH2B3 variant (E400K), by far the most common variant in the total cohort. 

Upon stratifying for presumptive germline status, 26 patients remained. 56% of the variants fall within the SH2 domain of the protein, much higher than the overall cohort. All but one of the variants are missense. Nine presented with MPNs, all of whom had additional driver variants. The median MPN age at diagnosis was 51 (range 21-79), including three patients below the age of 40, which is lower than the national average of 62 (Szuber, Natasha, et al. AJH 2018). One patient (with two variants) had confirmatory germline fibroblast testing; phenotype was notable for CVID, immune thrombocytopenia, massive splenomegaly, lymphoproliferation, granulomatous-lymphocytic interstitial lung disease, and vitiligo. 

Conclusions:

These findings contribute to the emerging understanding of the mutational landscape and clinical context of SH2B3 variants. Our findings underscore curation limitations as most variants were curated by the clinical laboratory as VUS. The observation of double-hit variants in a subset of patients including one with confirmatory germline fibroblast testing adds to the recognition that biallelic germline SH2B3 loss of function may define a distinct entity of myeloproliferation and multi-organ autoimmunity. For future aims, larger studies with functional characterization and definitive germline classification, a clear limitation of our study, will be essential to refine genotype-phenotype correlations, establish pathogenicity criteria, and inform surveillance.

Jack Tellerday, MD: No relevant conflicts of interest to declare.